Ask about this productRelated genes to: B3GALT6 antibody
- Gene:
- B3GALT6 NIH gene
- Name:
- beta-1,3-galactosyltransferase 6
- Previous symbol:
- -
- Synonyms:
- beta3GalT6
- Chromosome:
- 1p36.33
- Locus Type:
- gene with protein product
- Date approved:
- 2002-01-09
- Date modifiied:
- 2019-04-23
Related products to: B3GALT6 antibody
Related articles to: B3GALT6 antibody
- Occult intra-abdominal metastases are identified in approximately 20% of patients with radiographically localized pancreatic ductal adenocarcinoma (PDAC) through staging laparoscopy, as peritoneal cytology is limited in sensitivity. Methylated DNA markers (MDMs) have demonstrated high diagnostic accuracy for PDAC in tumor tissue, blood, and pancreatic secretions. This study assesses the feasibility and diagnostic performance of MDMs in peritoneal lavage fluid collected during staging laparoscopy, comparing their performance to mutant KRAS (mKRAS) detection. - Source: PubMed
Publication date: 2026/06/01
Mills KrystalBerger Calise KTaylor William RMahoney Douglas WBurger Kelli NMaheshwari KalikaKipp Benjamin RDelgado Adriana MDoering Karen AStreich Heather MFoote Patrick HCleary Sean PGrotz Travis EKendrick Micheal LSmoot Rory LStarlinger Patrick PThiels Cornelius ATruty Mark JWarner Susanne GKisiel John BMajumder Shounak - This study aims to reveal drug targets for sepsis: an association study integrating Mendelian randomization (MR), expression quantitative trait loci, protein quantitative trait loci, and protein-protein interaction networks. We identified 43 druggable proteins associated with sepsis, with B3GALT6 emerging as a key player (P = 5.24E-06). Sensitivity analyses indicated no significant heterogeneity among the proteins tested, reinforcing the robustness of our findings. Bioinformatics analyses demonstrated that B3GALT6 expression was significantly lower in sepsis patients compared to healthy controls across multiple datasets (P < .001), suggesting its potential utility as a diagnostic biomarker. Additionally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed critical pathways altered in sepsis, including multivesicular body assembly and ubiquitin-dependent protein catabolic processes. Our results highlight B3GALT6 as a promising therapeutic target and prognostic marker for sepsis, with implications for future research aimed at developing innovative treatment strategies. Overall, this study provides a foundation for further exploration of druggable proteins in sepsis, emphasizing the need for additional investigations to validate these findings in clinical settings and facilitate the translation of these insights into effective therapeutic interventions. - Source: PubMed
Lu EnkuiZhang YananShao XueboChen JunnanJiang MengpingTang Weidong - Proteoglycans are a major component of the connective tissue matrix, which consists of a core protein and covalently attached glycosaminoglycan (GAG) chains, which are highly sulfated polysaccharides with a tetrasaccharide linker for the core protein attachment. Impaired synthesis or degradation of GAG causes genetic disorders. In the 1950s, deficient lysosomal GAG degradation was discovered in mucopolysaccharidoses. In the 1990s, a defective enzyme for GAG synthesis was implicated in a variant of Ehlers-Danlos syndrome and an impaired GAG sulfation in diastrophic dysplasia. Newer studies have uncovered that abnormal GAG synthesis causes a large group of genetic skeletal disorders with joint and skin abnormalities. - Source: PubMed
Publication date: 2026/02/26
Tsujioka YukoSimsek Kiper Pelin OzlemUnger SheilaHanda AtsuhikoKono TatsuoJinzaki MasahiroRossi AntonioSuperti-Furga AndreaNishimura Gen - To explore the clinical phenotype and genetic etiology of a child with Ehlers-Danlos syndrome, spondylodysplastic type 2 (EDSSPD2). - Source: PubMed
Lan ShaocongLi ChengyanHuang BinglongChen YinhuiXie ZaoyeDeng WenhaoAo Dang - BACKGROUND: Prostate cancer (PCa) is characterized not merely as a malignant tumor, but also as a metabolic disorder encompassing dysregulation of glycolysis. This study was purposed to develop a new effective prognostic model correlated with glycolysis-related genes (GRGs) and investigate its potential mechanisms in PCa. METHODS: We compared the expression differences of GRGs. A glycolysis-associated prognostic model was then developed to categorize PCa patients into different risk subgroups. The diagnostic accuracy and predictive efficacy of the models were assessed. Furthermore, a comprehensive nomogram was developed, incorporating the risk score feature, T and N stage, Gleason score, and age, which was further calibrated for accuracy. Risk groups were analyzed for correlation with tumor-infiltrating immune cells (TIICs), immune function, and immunotherapy. In addition, we performed functional enrichment analyses. RESULTS: Through constructing Cytoscape regulatory networks, 10 hub genes were identified, and their significance was evaluated and validated. As a result, we confirmed 12 genes (B3GALT6, ANKZF1, IDUA, ENO2, ALDH1A3, GUSB, AURKA, CDK1, LDHB, ALDH3B2, GALM, and ADH1C) for prognostic modeling and calculation of risk scores. Mutations, TIICs, and drug sensitivity were also analyzed. Furthermore, the PTTG1, associated with glycolysis and tumor immunity, was confirmed in vivo. CONCLUSIONS: Overall, these findings underscore the prognostic relevance of glycolysis-related genes in prostate cancer and provide novel insights into their association with disease progression and the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/02/23
Wang JinhuaChen XiongYang GuoWang Xiaorong